Recombinant Human BCL2 Protein(GST Tag) (PDEH101111)
For research use only.
| Synonyms | B-cell Lymphoma, PPP1R, BCL, Bcl-2, PPP1R50, BCL2, apoptosis regulator Bcl-2, B-cell Lymphoma 2, apoptosis regulator Bcl-2, Bcl-2, PPP1R50, Apoptosis regulator Bcl 2, Apoptosis regulator Bcl2, AW986256, B cell CLL/lymphoma 2, B cell leukemia/lymphoma 2, B-cell, C430015F12Rik, D630044D05Rik, D830018M01Rik, Leukemia/lymphoma, Oncogene B-cell leukemia 2, Protein phosphatase 1, regulatory subunit 50, Bcl2 |
| Species | Human |
| Expression Host | E.coli |
| Sequence | Met1-Asp211 |
| Accession | P10415 |
| Calculated Molecular Weight | 49.2 kDa |
| Observed Molecular Weight | 50 kDa |
| Tag | N-GST |
| Bio-activity | Not validated for activity |
| Purity | > 95% as determined by reducing SDS-PAGE. |
| Endotoxin | < 10 EU/mg of the protein as determined by the LAL method |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol. |
| Reconstitution | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis |
| Background | BCL2-like 12 (BCL2L12 ) is a new member of the apoptosis-related BCL2 gene family, members of which are implicated in various malignancies. The mRNA expression of BCL2L12 may constitute a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma. BCL2L12 is a recently identified gene belonging to the BCL2 family, members of which are implicated in hematologic malignancies, including chronic lymphocytic leukemia (CLL). BCL2L12 can be considered as a new independent prognostic and chemotherapy response marker in AML. BCL2L12 mRNA expression may serve as a potential prognostic biomarker in tongue and/or larynx SCC, which principally constitute the great majority of HNSCC cases worldwide. BCL2L12 mRNA expression is a favorable prognostic marker of DFS for BC patients, suggesting its possible application as a novel prognostic indicator of this malignancy. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
